Skip to content
MARKETS / NASDAQ / AVTX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Avalo Therapeutics, Inc. AVTX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$59,000
▼ 86.6% YoY
$-78.3M
Growth
USD 59,000.00
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.1 · Net income -78.3
10M20M-40M-80M2013201520172019202120232025
Compound annual growth
−85.2%
−61.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −61.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−132642 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -123601.7% · Net -132642.4%
-50000%-100000%2013201520172019202120232025
ROE
FY2025 · ROE -72.4%
50%-200%-400%-600%2013201520172019202120232025

Each USD of equity lost 72 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -26.8
5.0M10.0M-25.0M-50.0M2013201520172019202120232025

Total assetsUSD 116.5M
EquityUSD 83.0M
CashUSD 15.9M
Current ratio8.14×

Equity funds 71% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0··
Operating income $B−0.1−0.1−0.0−0.0−0.1−0.1−0.0−0.00.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.0−0.0−0.1−0.1−0.0−0.00.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0−0.0−0.00.0−0.00.00.00.0··
Net income $B−0.1−0.0−0.0−0.0−0.1−0.1−0.0−0.00.0−0.0−0.0−0.0−0.0
Free cash flow $B···−0.0−0.1−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
EPS, diluted $−5.84−20.91−113.58····−1.200.42−1.87−4.71−5.48−20.72
Dividend / sh $·············
Payout %·············
ROE %−72.4−50.1·−684.8−354.2−278.8−76.7−164.384.6−247.9···
Shares out B0.020.010.000.000.010.080.040.040.030.010.010.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 46 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 40 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image